MiniMed Completes Share Exchange With Medtronic; Medtronic Now Owns No MiniMed Stock

What happened

MiniMed Group, Inc., a Northridge, California-based maker of diabetes technology that trades on Nasdaq under the ticker MMED, said on October 15, 2026 that its previously announced exchange offer was completed, according to an 8-K filed with the SEC on October 16.

Under the offer, Medtronic plc shareholders tendered 55,032,401 Medtronic ordinary shares and received 252,813,348 newly issued MiniMed common shares in return. MiniMed said that as a result, Medtronic no longer owns any shares of MiniMed common stock.

The offer was for up to 252,813,348 MiniMed shares and was described in a Form S-4 registration statement filed September 14, 2026, including a final prospectus filed October 5, 2026.

Separately, four directors — Linnea Burman, Scott Cundy, Laura Mauri and Matthew R. Walter — resigned effective October 15. The filing states that none of the resignations resulted from any disagreement with management or the board over operations, policies or practices.

The board shrank from 11 to eight members and appointed Amy Bricker, currently Executive Vice President and Chief Enterprise Pharmacy Officer at Walgreen Co., as a director to fill the vacancy, effective October 15. She will serve as a Class II director with a term expiring at the 2027 annual meeting and will sit on the Nominating and Corporate Governance Committee. The board determined she is independent under Nasdaq, SEC and company guidelines.

The board also amended its non-employee director compensation policy to provide a pro-rated annual grant of restricted stock units to people who join the board between annual meetings. The full policy will be filed as an exhibit to the company's quarterly report for the quarter ending October 30, 2026.

MiniMed shares closed at $17.49 on the event date, down 2.83% from the prior close of $18.00, according to the price data.

The exchange offer

An exchange offer is a transaction in which one company issues its own shares to holders of another company's stock in place of that stock. Here, people who owned Medtronic ordinary shares could tender them and receive MiniMed common stock instead.

Before the offer closed, Medtronic held a stake in MiniMed. The exchange moved that stake directly to Medtronic's own shareholders: 55,032,401 Medtronic shares were accepted in exchange for 252,813,348 MiniMed shares, and MiniMed said Medtronic's ownership of MiniMed common stock fell to zero.

The filing does not explain why the transaction was structured this way or what strategic purpose it served. It describes the mechanics and the results only. Readers should not assume a reason beyond what the company disclosed.

The board changes

The four resignations and the appointment of Amy Bricker took effect on the same day the exchange offer closed, and the filing frames them as occurring "in connection with" completion of the offer.

Item 5.02 of Form 8-K is the section companies use to report the departure or arrival of directors and certain executives, and any changes to how they are paid. In this filing, the company used it to disclose both the resignations and Bricker's appointment, as well as the amended director pay policy.

The amended policy covers a specific gap: directors who join partway through the year, rather than at the annual shareholder meeting, receive a pro-rated annual grant of restricted stock units — shares delivered later, subject to vesting conditions — instead of nothing until the next annual meeting. Bricker's pay will follow the same policy as other non-employee directors.

The filing does not say why the board was reduced to eight members or why these four directors in particular stepped down.

What this means

A Form 8-K is the form a US-listed company must file with the SEC to disclose material events to investors, generally within four business days. The numbered "items" indicate which category of event is being reported. This filing invokes Item 5.01 (a change in control of the company), Item 5.02 (director and officer changes), Item 7.01 (Regulation FD, a rule requiring companies to disclose information to all investors at once rather than selectively) and Item 9.01 (financial statements and exhibits, here the press release announcing the completion).

Item 5.01 applies because the transaction changed who controls MiniMed: Medtronic's stake went to zero and the shares moved to former Medtronic shareholders. For a reader trying to understand the filing, the key point is that control did not shift to a single new owner; it dispersed to the tendering Medtronic shareholders and, presumably, to MiniMed's existing public holders.

Item 7.01 is a "furnished" disclosure rather than a "filed" one. The distinction matters legally: the press release attached as Exhibit 99.1 is not subject to the liability provisions of Section 18 of the Securities Exchange Act and is not automatically incorporated into other filings. In plain terms, it is the company putting the announcement on the public record.

The filing does not forecast what happens next. It does not address MiniMed's future ownership structure beyond stating Medtronic's holding is now zero, and it gives no financial results or guidance. The next scheduled disclosure referenced in the filing is the quarterly report for the fiscal quarter ending October 30, 2026, which will carry the amended director compensation policy as an exhibit.